OMIX

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic cancer after previous gemcitabine-based therapy: a randomised, double-blind, parallel-controlled, multicentre phase 3 trial

OMIX004438

1Summary
Title Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic cancer after previous gemcitabine-based therapy: a randomised, double-blind, parallel-controlled, multicentre phase 3 trial
Description Liposomal irinotecan has shown promising antitumour activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma who have been treated with gemcitabine-based therapies. This phase 3 trial assessed the efficacy and safety of a novel liposomal irinotecan HR070803 in combination with 5-fluorouracil and leucovorin in this population.
Organism Homo sapiens
Data Type Clinical Research data
Data Accessibility Controlled-access
BioProject PRJCA017910
Release Date 2023-12-31
Submitter binbin liu (binbin.liu@hengrui.com)
Organization Jiangsu Hengrui Pharmaceutical Co., Ltd
Submission Date 2023-06-28
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download Times Download
OMIX004438-01 Clinical data 1 Clinical Research data 314.4 KB pdf 0 Controlled

Request for this Data View All Released Data of OMIX